Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 10/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8484431 | 0.89 | L3MBTL1 (0.35) | — | |
| SCHEMBL8666043 | 0.87 | HTT (0.33) | C5AR1 | |
| SCHEMBL8479245 | 0.84 | SCN1A (0.39) | SCN1ASCN5ASCN9AAOC3NPY1R | |
| SCHEMBL8504363 | 0.84 | KCNA5 (0.30) | — | |
| SCHEMBL8664320 | 0.81 | SCN1A (0.36) | SCN1ASCN5ASCN9AAOC3NPY1R | |
| SCHEMBL8479703 | 0.81 | CCR3 (0.42) | MCHR1 | |
| SCHEMBL8479389 | 0.81 | DPP4 (0.38) | DPP4SCN1ASCN5ASCN9AAOC3 | |
| SCHEMBL8484683 | 0.80 | SCN1A (0.40) | SCN1ASCN5ASCN9AAOC3NPY1R | |
| SCHEMBL8480404 | 0.80 | SCN1A (0.39) | SCN1ASCN5ASCN9AAOC3NPY1R | |
| SCHEMBL8487923 | 0.79 | SCN1A (0.38) | SCN1ASCN5ASCN9AAOC3NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5883099-A | TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| US-H1729-H | Method for preparing compounds employing solid phase synthesis and novel linker-resin | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| US-5739135-A | PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-14 | — | — | US | disclosed |